keyword
MENU ▼
Read by QxMD icon Read
search

oncology lymphoma

keyword
https://www.readbyqxmd.com/read/29772611/evaluation-of-two-prognostic-indices-for-adult-t-cell-leukemia-lymphoma-in-the-subtropical-endemic-area-okinawa-japan
#1
Keita Tamaki, Satoko Morishima, Shogo Nomura, Yukiko Nishi, Sawako Nakachi, Sakiko Kitamura, Sachie Uchibori, Shouhei Tomori, Taeko Hanashiro, Natsuki Shimabukuro, Iori Tedokon, Kazuho Morichika, Naoya Taira, Takeaki Tomoyose, Takashi Miyagi, Kaori Karimata, Masayo Ohama, Atsushi Yamanoha, Kazumitsu Tamaki, Masaki Hayashi, Jun-Nosuke Uchihara, Kazuiku Ohshiro, Yoshitaka Asakura, Megumi Kuba-Miyara, Kennosuke Karube, Takuya Fukushima, Hiroaki Masuzaki
Aggressive adult T-cell leukemia/lymphoma (ATL) has an extremely poor prognosis and is hyperendemic in Okinawa, Japan. This study evaluated two prognostic indices (PIs) for aggressive ATL, the ATL-PI and Japan Clinical Oncology Group (JCOG)-PI, in a cohort from Okinawa. The PIs were developed using two different Japanese cohorts that included few patients from Okinawa. The endpoint was overall survival (OS). Multivariable Cox regression analyses in the cohort of 433 patients revealed that all seven factors for calculating each PI were statistically significant prognostic predictors...
May 17, 2018: Cancer Science
https://www.readbyqxmd.com/read/29769263/how-i-treat-burkitt-lymphoma-in-children-adolescents-and-young-adults-in-sub-saharan-africa
#2
Satish Gopal, Thomas G Gross
Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa (SSA), and also occurs frequently among adolescents and young adults (AYA), often associated with human immunodeficiency virus (HIV). Treating BL in SSA poses particular challenges. Although highly effective, high-intensity cytotoxic treatments used in resource-rich settings are usually not feasible, and lower-intensity continuous infusion approaches are impractical. In this paper, based on evidence from the region, we review management strategies for SSA focused on diagnosis, use of pre-phase, and definitive treatment...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29767316/-ceus-diagnosis-of-solid-renal-tumors
#3
REVIEW
K Stock, H Kübler, T Maurer, J Slotta-Huspenina, K Holzapfel
CLINICAL ISSUE: Renal lesions are detected earlier, often as a result of ultrasound examinations. However, the imaging-based differential diagnosis of different tumour entities remains challenging STANDARD RADIOLOGICAL METHODS: All renal tumours >1 cm should be evaluated for malignancy by computed tomography (CT) or magnetic resonance imaging (MRI). If an angiomyolipoma diagnosis cannot be established with imaging, further diagnostics are appropriate or if malignant progression is suspected, then multidisciplinary discussion for TNM-staging based uro-oncologic therapy is usual...
May 16, 2018: Der Radiologe
https://www.readbyqxmd.com/read/29752199/gemcitabine-oxaliplatin-plus-rituximab-r-gemox-as-first-line-treatment-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-single-arm-open-label-phase-2-trial
#4
Qiu-Dan Shen, Hua-Yuan Zhu, Li Wang, Lei Fan, Jin-Hua Liang, Lei Cao, Wei Wu, Yi Xia, Jian-Yong Li, Wei Xu
BACKGROUND: The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma. We aimed to evaluate the efficacy, safety, and feasibility of the R-GemOx regimen as a first-line treatment in elderly patients with diffuse large B-cell lymphoma. METHODS: In this single-arm, open-label, phase 2 clinical trial, we enrolled patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60-69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater...
May 8, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29747287/-a-comparative-study-of-comprehensive-geriatric-assessment-in-elder-patients-with-non-hodgkin-s-lymphoma
#5
H Liu, M Gao, D Mei, H X Han, J T Li, J F Bai, C L Zhang, R Feng, J P Wei, Y Tian, T Wang
Objective: To measure the comprehensive geriatric assessment (CGA) in elder non-Hodgkin's Lymphoma (NHL) patients in a cross-sectional study; to compare the differences between Eastern Cooperative Oncology Group (ECOG)-performance status (PS) and CGA. Methods: CGA stratification included the following 3 instrument assessments: activity of daily living (ADL);instrumental activity of daily living (IADL);comorbidity score according to the modified cumulative illness rating score for geriatrics (MCIRS-G). According to CGA and age, NHL patients, aged ≥60 years, were classified as"fit","unfit"and"frail"groups...
May 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29742194/widespread-skin-necrosis-secondary-to-gemcitabine-therapy
#6
Patrick M Zito, Adrianna M Gonzalez, Joshua D Fox, Megan Cronin, Nicholas Mackrides, Robert S Kirsner, Anna J Nichols
Gemcitabine, a pyrimidine nucleoside analogue, is an oncologic agent used in the treatment of cutaneous T-cell lymphoma (CTCL). Common dermatologic reactions associated with gemcitabine include alopecia, mild skin rash, and mucositis but skin necrosis is exceptional. Herein we present an unusual case of widespread skin necrosis mimicking toxic epidermal necrolysis in a 45-year-old woman receiving gemcitabine therapy for stage IIIA cutaneous T-cell lymphoma. This is the first reported case of a TEN-like reaction subsequent to gemcitabine treatment...
May 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29741105/systematic-literature-review-of-health-related-quality-of-life-among-aggressive-non-hodgkin-lymphoma-survivors
#7
Vincent W Lin, Barbara Blaylock, Josh Epstein, Anna Purdum
OBJECTIVE: Literature have shown that a proportion of patients with aggressive non-Hodgkin lymphoma (NHL) treated with standard chemotherapy will have long-term life expectancy comparable to those in the age-adjusted general population (Maurer et al. 2014). This systematic literature review summarizes current literature regarding health-related quality of life (HRQoL) of long-term (≥2 years) survivors of aggressive NHL. METHODS: Electronic databases (without restriction on years) and abstracts from four major oncology and HRQoL conferences from 2014-2017 were searched...
May 9, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29739348/cancer-incidence-in-yemen-from-1997-to-2011-a-report-from-the-aden-cancer-registry
#8
Amen Ahmed Bawazir
BACKGROUND: This study aims to report on the trend and incidence of cancers in Yemen (Aden) using data from Aden Cancer Registry (ACR), as a population-based cancer registry in Yemen over a period of 15 years (1997-2011). Such comprehensive, valid and detailed information on cancer trend is badly needed for planning a cancer control program in the country. METHODS: All cancer cases were abstracted from patients' medical records - based on clinical, histopathology, and radiological diagnosis...
May 8, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29738613/results-of-the-ahod0431-trial-of-response-adapted-therapy-and-a-salvage-strategy-for-limited-stage-classical-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group
#9
Frank G Keller, Sharon M Castellino, Lu Chen, Qinglin Pei, Stephan D Voss, Kathleen M McCarten, Stacy L Senn, Allen B Buxton, Rizvan Bush, Louis S Constine, Cindy L Schwartz
BACKGROUND: The Children's Oncology Group AHOD0431 study evaluated a response-directed treatment paradigm in which minimal initial chemotherapy and low-dose radiation was received only by patients who did not achieve a complete remission, and a chemotherapy/low-dose radiation salvage regimen was received by those who had a protocol-defined, low-risk recurrence. METHODS: Patients younger than 21 years who had stage IA or IIA nonbulky disease were eligible. The treatment strategy was evaluated by determining the proportion that received minimal chemotherapy alone, the proportion that had a first or second remission without the receipt of high-dose chemotherapy/stem cell rescue or higher dose involved-field radiation therapy (>21 grays), and overall survival...
May 8, 2018: Cancer
https://www.readbyqxmd.com/read/29722656/patterns-of-involved-field-radiation-therapy-protocol-deviations-in-pediatric-versus-adolescent-and-young-adults-with-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group-ahod0031
#10
Aaron Parzuchowski, Rizvan Bush, Qinglin Pei, Debra L Friedman, Thomas J FitzGerald, Suzanne L Wolden, Kavita V Dharmarajan, Louis S Constine, Fran Laurie, Sandy K Kessel, Burton Appel, Karen Fernandez, Angela Punnett, Cindy L Schwartz, Jacob Cox, Stephanie A Terezakis
PURPOSE: The presented protocol for pediatric intermediate-risk Hodgkin lymphoma evaluated the use of a dose-intensive chemotherapy regimen (ABVE-PC [doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, prednisone]) with response-based therapy augmentation (addition of DECA [dexamethasone, etoposide, cisplatin, cytarabine]) or therapy reduction (elimination of radiation). METHODS AND MATERIALS: A central review of the radiation therapy data for quality assurance was performed, and the association between radiation protocol deviation (RPD) and relapse was assessed in the pediatric group (age <15 years) and adolescent and young adult (AYA) group (age ≥15-21 years)...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29722655/the-role-of-radiation-therapy-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-guidelines-from-the-international-lymphoma-radiation-oncology-group
#11
REVIEW
Louis S Constine, Joachim Yahalom, Andrea K Ng, David C Hodgson, Andrew Wirth, Sarah A Milgrom, N George Mikhaeel, Hans Theodor Eich, Tim Illidge, Umberto Ricardi, Karin Dieckmann, Craig H Moskowitz, Ranjana Advani, Peter M Mauch, Lena Specht, Richard T Hoppe
Relapsed and refractory Hodgkin lymphoma (HL) challenges clinicians to devise treatment strategies that are effective and safe. This problem is particularly prominent in an era when de-escalation trials are designed to minimize therapeutic toxicities in both early- and advanced-stage disease. Radiation therapy is the single most effective treatment modality for HL, and its integration into salvage regimens, or its independent use in select patients, must be understood to maximize our success in treating these patients...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29721249/extranodal-diffuse-large-b-cell-lymphomas-a-retrospective-case-series-and-review-of-the-literature
#12
Stergios Boussios, Ioannis Zerdes, Amalia Vassou, Eleni Bareta, Esmeralda Seraj, Alexandra Papoudou-Bai, Nicholas Pavlidis, Anna Batistatou, George Pentheroudakis
Non-Hodgkin lymphomas commonly show extranodal involvement (25-30%) but primary diffuse large B-cell lymphomas (DLBCL) with extranodal localization represent clinically and molecularly distinct entities. The present study involved retrospective analysis of case records of 4 patients who were diagnosed with extranodal DLBCL between 2010 and 2016 at the Medical Oncology and Hematology Departments of the Ioannina University Hospital, Greece. Median age of presentation was 69 years (range 60-77 years). There were 2 males and 2 females...
March 2, 2018: Hematology Reports
https://www.readbyqxmd.com/read/29703767/encephalitis-with-mglur5-antibodies-symptoms-and-antibody-effects
#13
Marianna Spatola, Lidia Sabater, Jesús Planagumà, Eugenia Martínez-Hernandez, Thaís Armangué, Harald Prüss, Takahiro Iizuka, Ruben L Caparó Oblitas, Jean-Christophe Antoine, Richard Li, Nicholas Heaney, Niall Tubridy, Elvira Munteis Olivas, Myrna R Rosenfeld, Francesc Graus, Josep Dalmau
OBJECTIVE: To report the clinical features of 11 patients with metabotropic glutamate receptor 5 (mGluR5) antibody-associated encephalitis, immunoglobulin G (IgG) subclass, and effects of the antibodies on neuronal mGluR5 clusters. METHODS: Clinical information was retrospectively obtained from referring physicians. Antibodies to mGluR5 and IgG subclasses were determined with brain immunohistochemistry and cell-based assays. The effects of the antibodies were examined on rat hippocampal neurons with reported techniques...
April 27, 2018: Neurology
https://www.readbyqxmd.com/read/29701370/major-complications-of-videomediastinoscopy-and-their-resolution-a-5-year-experience
#14
Ana Rita Costa, João Silva, João Eurico, Manuel Godinho, Rita Barata, Ivan Bravio, Paulo Calvinho, José Fragata
INTRODUCTION: Videomediastinoscopy is an invasive procedure for mediastinal assessment, with low rates of morbidity and mortality. Despite the low risk of complications, they can be potentially lethal if not immediately controlled. OBJECTIVE: The goal of this study is to analyse the overall incidence of complications of videomediastinoscopies, performed in the last 5 years at our department, as well as their resolution and outcomes. METHODS: A retrospective review of all videomediastinoscopies performed at a single institution during a 5-year period was performed...
July 2017: Revista Portuguesa de Cirurgia Cardio-torácica e Vascular
https://www.readbyqxmd.com/read/29691269/implementation-of-a-pharmacy-managed-program-for-the-transition-of-chemotherapy-to-the-outpatient-setting
#15
Ali McBride, Christopher J Campen, James Camamo, Marie Maloney, Daniel Persky, Sandra E Kurtin, Nikki L Barket, Ravitharan Krishnadasan, Emad Elquza, Faiz Anwer, Kurt Weibel
PURPOSE: Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting is described. SUMMARY: The University of Arizona Cancer Center and Banner-University Medical Center Tucson are affiliated not-for-profit academic medical centers in Tucson, Arizona, whose facilities include a hospital and ambulatory care clinics that maintain 3 outpatient infusion centers. The cancer center pharmacy currently employs 25 pharmacists, with 4 clinical pharmacists serving both the inpatient and outpatient treatment sites...
May 1, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29681201/cost-effectiveness-vs-affordability-in-the-age-of-immuno-oncology-cancer-drugs
#16
George Dranitsaris, Xiaofu Zhu, Georges Adunlin, Mark D Vincent
After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improved quality-of-life. Using the immune system to treat cancer is known as 'Immuno-oncology' (IO) and agents are sub-classified by their ability to enhance anti-tumor response or to direct the immune system to attack cancer cells via tumor-associated antigens. Areas covered: Clinical trials have demonstrated the effectiveness of several IO agents in many disease sites such as early and advanced stage melanoma, advanced non-small cell lung cancer, bladder, head and neck, gastric, kidney as well as Hodgkin's lymphoma...
April 25, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29673807/frequency-and-impact-of-grade-three-or-four-toxicities-of-novel-agents-on-outcomes-of-older-patients-with-chronic-lymphocytic-leukemia-and-non-hodgkin-lymphoma-alliance-a151611
#17
Michael Tallarico, Jared C Foster, Drew Seisler, Jacqueline M Lafky, Arti Hurria, Aminah Jatoi, Harvey J Cohen, Hyman B Muss, Nancy Bartlett, Bruce D Cheson, Sin-Ho Jung, John P Leonard, John C Byrd, Chadi Nabhan
OBJECTIVE: Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients. As novel agents are being used more commonly in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), toxicities of these agents in older patients have not been well studied. Further, impact of these toxicities on outcomes in the elderly is unknown. This study aimed to answer both questions. PATIENTS AND METHODS: We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004-2014...
April 16, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29669701/crizotinib-in-patients-with-advanced-inoperable-inflammatory-myofibroblastic-tumours-with-and-without-anaplastic-lymphoma-kinase-gene-alterations-european-organisation-for-research-and-treatment-of-cancer-90101-create-a-multicentre-single-drug-prospective-non
#18
Patrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, Jean-Yves Blay, Sandra J Strauss, Silvia Stacchiotti, Piotr Rutkowski, Lars H Lindner, Michael G Leahy, Antoine Italiano, Nicolas Isambert, Maria Debiec-Rychter, Raf Sciot, Thomas Van Cann, Sandrine Marréaud, Axelle Nzokirantevye, Sandra Collette, Agnieszka Wozniak
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK)...
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29650362/tazemetostat-an-ezh2-inhibitor-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-and-advanced-solid-tumours-a-first-in-human-open-label-phase-1-study
#19
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, Jean-Marie Michot, Carlo Lucchesi, Andrea Varga, Jean-Michel Coindre, Stephen J Blakemore, Alicia Clawson, Benjamin Suttle, Alice A McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A Copeland, Peter T C Ho, Vincent Ribrag
BACKGROUND: Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to aberrant histone methylation, oncogenic transformation, and a proliferative dependency on EZH2 activity. In this first-in-human study, we aimed to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of EZH2...
April 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29649329/overview-and-outcome-of-hodgkin-s-lymphoma-experience-of-a-single-developing-country-s-oncology-centre
#20
Rawand P Shamoon, Mohamad Dahir Ali, Nazar P Shabila
Hodgkin's Lymphoma (HL) reveals variable epidemiological and clinico-pathological features in different geographical locations. In this retrospective study, we aimed to assess the epidemiological and clinic-pathological features, and outcome of HL patients treated at one hemato-oncology centre in Erbil, northern Iraq. Medical records of 103 HL patients treated over more than six years were reviewed. Treatment outcome was evaluated by measuring the 5-year overall and progression-free survival rates. The median age of patients was 23 years, children up to 17 years constituted 31...
2018: PloS One
keyword
keyword
63324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"